Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations

P.Y. Ng,Y.C. Han, L. Shin Ogawa, R. Schulz, S.N. Yang, I. Jewett,N. Ishiyama, D. Romashko, A. Salomatov,S. Thakur,M. Lucas, T.A. Lin,E. Buck

European Journal of Cancer(2022)

引用 0|浏览3
暂无评分
关键词
brain penetrant masterkey inhibitor,mutations
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要